Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

To be part of this study, you need to be at least 18 years old and have been diagnosed with early-stage oesophageal adenocarcinoma. This means the cancer is either in stage T1 or T2 and hasn't spread to any nearby lymph nodes or other parts of the body (N0 M0).

Doctors will also need to confirm that your tumour was initially considered suitable for surgery. Some specific details about your tumour, including a test called PD-L1 CPS, must also be available from recent biopsies. You should also be generally well enough to take part in the study, meaning you have a good level of physical activity.

Important points that would mean you can't join include having received previous chemotherapy or radiotherapy for this cancer, or if you've already had surgery to remove your oesophageal tumour.

If you join this study, you would first have a series of treatments. This involves receiving the immunotherapy drug durvalumab alongside two cycles of FLOT chemotherapy. After this, you would continue with durvalumab, but switch to a different chemotherapy called mFOLFOX-6, which you would have for three cycles. During this time, you would also receive radiotherapy.

After these treatments, about eight weeks later, you'll have detailed checks to see how the cancer has responded. These checks include endoscopies (where a thin tube with a camera is passed down your throat) with biopsies, internal ultrasound scans, and CT or MRI scans. If your cancer has completely gone, you would then move into a 'maintenance' phase, receiving durvalumab alone for up to 12 more cycles. Throughout the study, you'll have regular appointments to monitor your health and how you're responding to treatment.